Navigation Links
Tumor genome analysis unveils new insights into lung cancer
Date:11/4/2007

An international consortium of scientists today in an advanced online publication in the journal Nature revealed a comprehensive view of the altered genetic background of the type of lung cancer that is the most common cause of cancer deaths in humans.

Of particular interest was a specific proto-oncogene called NKX2-1 that appears involved in as many as 12 percent of lung adenocarcinomas the most common cause of cancer deaths worldwide, said the group, whose work was in part financed by the National Human Genome Research Institute (NHGRI). The group noted, however, that analysis indicates that many of the genes that play a role in the disease remain to be discovered.

This view of the lung cancer genome is unprecedented, both in its breadth and depth, said senior author Dr. Matthew Meyerson, a senior associate member of the Broad Institute of MIT and Harvard in Cambridge, Mass., and an associate professor at Dana-Farber Cancer Institute and Harvard Medical School in Boston. It lays an essential foundation, and has already pinpointed an important gene that controls the growth of lung cells. This information offers crucial inroads to the biology of lung cancer and will help shape new strategies for cancer diagnosis and therapy

The report is the first to emerge from the Tumor Sequencing Project that involves three genome centers: Baylor College of Medicine Human Genome Sequencing Center in Houston, The Broad Institute of Harvard and MIT in Cambridge, Mass., and Washington University in St. Louis, Mo.; and five cancer centers: Dana-Farber Cancer Institute in Boston, The University of Texas M. D. Anderson Cancer Center in Houston, Memorial Sloan-Kettering Cancer Center in New York, the University of Michigan and Washington University.

Each year, more than 1 million people worldwide die of lung cancer. In the United States, the annual death toll is 150,000. Lung adenocarcinoma, the topic of this study, is the most common cause of
'/>"/>

Contact: Glenna Picton
picton@bcm.edu
713-798-4710
Baylor College of Medicine
Source:Eurekalert

Page: 1 2 3

Related biology news :

1. Mouse brain tumors mimic those in human genetic disorder
2. Researchers add new tool to tumor-treatment arsenal
3. Self-assembled nano-sized probes allow Penn researchers to see tumors through flesh and skin
4. Pulsating ultrasound enhances gene therapy for tumors
5. Scientists identify molecule that regulates well-known tumor suppressor
6. New tumor-suppressor gene discovered
7. NSAID drug protects against intestinal tumors in mice, despite poor diet and gene losses
8. Natural tumor suppressor in body discovered by UCSD medical researchers
9. Unexpected lock and key mechanism found for the assembly of tumor blood vessels
10. Double trouble: Cells with duplicate genomes can trigger tumors
11. Novel regulatory mechanism identified for key tumor suppressor p53
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/11/2014)... 2014 Research and Markets ... ( http://www.researchandmarkets.com/research/9ql3kr/biometrics_market ) has announced the addition of ... report to their offering. One ... adoption of multimodal biometric systems. Multimodal biometric systems ... for verification and identification purposes. This helps to ...
(Date:12/10/2014)... -- Valencell, a leader in performance biometric data sensor technology, ... its licensees for highly accurate, clinically validated biometric technology. ... from fitness and health sectors, but first responders/military and ... only as useful as the biometric data it delivers. ... long-term mass consumer adoption of wearable products," said Dr. ...
(Date:12/10/2014)... 9, 2014     ...   Jifflenow, a ... solutions for business-to-business (B2B) events, today announced a ... mobile near-field communication (NFC), Bluetooth low energy (BLE), ... http://photos.prnewswire.com/prnh/20140612/691055) , Jifflenow will integrate its ...
Breaking Biology News(10 mins):Biometrics Market in India 2015-2019: Key Vendors are 3M Cogent, NEC, Safran and Suprema 2Wearable Technology Products Demand Highly Accurate Biometric Technology 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 2Jifflenow And ITN International Bring Cutting-Edge Badge Scanning Technology To B2B Events 3
... 2011 Reportlinker.com announces that a new market ... Biobanking: Technologies and Global Markets ... REPORT HIGHLIGHTS THIS REPORT ... biobanks by types: Population, Disease, and Private Sector ...
... YORK, July 14, 2011 ,   ... for consumer wellness applications,today announced that it has entered into ... US$5 Million equity,line facility. Under the terms of ... has the option to sell and Dutchess the,obligation to purchase ...
... Aware, Inc. (NASDAQ: AWRE ), a leading supplier ... its second quarter ended June 30, 2011.   Revenue ... of 19% compared to $5.0 million in the same quarter last ... $267,000, or $0.01 per diluted share. These results compared to a ...
Cached Biology News:Biobanking: Technologies and Global Markets 2Biobanking: Technologies and Global Markets 3Biobanking: Technologies and Global Markets 4Biobanking: Technologies and Global Markets 5Biobanking: Technologies and Global Markets 6Biobanking: Technologies and Global Markets 7Biobanking: Technologies and Global Markets 8Biobanking: Technologies and Global Markets 9Biobanking: Technologies and Global Markets 10Biobanking: Technologies and Global Markets 11Biobanking: Technologies and Global Markets 12Biobanking: Technologies and Global Markets 13SPO Secures Equity Line Facility of US$5 Million 2SPO Secures Equity Line Facility of US$5 Million 3SPO Secures Equity Line Facility of US$5 Million 4Aware, Inc. Reports Second Quarter 2011 Financial Results 2Aware, Inc. Reports Second Quarter 2011 Financial Results 3Aware, Inc. Reports Second Quarter 2011 Financial Results 4Aware, Inc. Reports Second Quarter 2011 Financial Results 5
(Date:12/24/2014)... ST. LOUIS , Dec. 23, 2014 /PRNewswire/ ... announced today that the waiting period under the ... with the acquisition expired on December 22, 2014, ... and review requirement for the acquisition of the ... U.S. antitrust clearance satisfies another condition to ...
(Date:12/22/2014)... Dec. 22, 2014   Synthetic Biologics, ... of pathogen-specific therapies for serious infections and ... microbiome, today announced positive topline safety and ... trial of SYN-004, the Company,s investigational oral ... Clostridium difficile (C. difficile) infection, antibiotic-associated ...
(Date:12/22/2014)... , Dec. 22, 2014  ( www.competitivehealth.com ) — ... online medical bill review and advocacy service, has signed ... FREE WellCard Savings discount health services marketplace. ... was more than they expected to pay. As part ... care costs, WellCard Savings is pleased to offer medical ...
(Date:12/19/2014)... and Hershey, PA (PRWEB) December 19, 2014 ... BJCT), a leading developer and manufacturer of needle-free ... into an agreement with Immunomic Therapeutics, Inc. (“ITI”) ... needle-free injection device with its LAMP™ vaccine platform. ... option for an exclusive Worldwide license to the ...
Breaking Biology Technology:Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 2Acquisition of Sigma-Aldrich by Merck KGaA, Darmstadt, Germany, Receives U.S. Antitrust Clearance 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 2Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 3Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 4Synthetic Biologics Announces Positive Topline Results from Phase 1a Trial of SYN-004 for the Prevention of C. difficile Infection 5WellCard Savings Announces CoPatient Medical Bill Review Service for Members 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 2Bioject and Immunomic Therapeutics Enter into an Agreement for License of Needle-Free Technology for LAMP-vax Vaccines 3
... Australia, Jan. 30 Phosphagenics,Limited ("Phosphagenics") (ASX: POH, ... pre-clinical study demonstrating that the,combination of its APA- ... reduced serum lipids and inflammatory proteins,involved in the ... purpose of the study was to determine whether ...
... 30 Sagent Pharmaceuticals, Inc.,a privately-held specialty pharmaceutical ... that Ronald E. Pauli, chief financial,officer, will present ... Device Conference on Tuesday, February 5, 2008,at 11 ... 5-7, 2008 at the Grand,Hyatt Hotel in New ...
... Medical,Inc. (TASE: TOPMD) announces first commercial installation of ... Belgium,with the first procedures performed on January 16th., ... site to install the Cathamaran(TM),IVMRI System. This 6F ... to detect and quantify lipid present in coronary ...
Cached Biology Technology:Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 2Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 3Phosphagenics Reports Superior Pre-clinical Cholesterol Results from APA-01 and Atorvastatin Combination 4Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System 2Topspin Medical Announces First Commercial Installation of the Cathamaran(TM) Intravascular MRI System 3
... Detection of the yolk protein Vtg in plasma ... and sensitive biomarker for endocrine disrupting chemicals (EDCs) ... has become an accepted screening test for the ... (rainbow trout) EIA kit is a double-antibody immunometric ...
... whose sequence is from rat SCAMP 5. The sequence of ... - Q - P - Q - T - Q - ... - Y - T - Y - S - N(233). ... with the polyclonal antibody that reacts with this product and the ...
... which no antibody exists? Having difficulty generating antibodies ... variety of pharmaceutical, biotech and academic researchers and ... and expertise in antibody generation to work for ... development technology , High affinity and high specificity ...
... Panels were designed for full-length gene cloning ... to identify the desired cDNA clone. The ... 96-well "Master Plate," where each well contains ... the positive well(s) by gel electrophoresis of ...
Biology Products: